Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
Overview
The tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database. Deep learning will be carried out by computer and artificial intelligence to construct the early screening, diagnosis, prognosis and prognosis model of various malignant tumors based on tongue image for the diagnosis and treatment of malignant tumors.
Full Title of Study: “A Multi-center Observational Clinical Study Observing the Differences of Tongue Images Between Patients With Malignant Tumors and Healthy People”
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: February 1, 2022
Interventions
- Other: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
- Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Arms, Groups and Cohorts
- Patients with malignant tumors and healthy people
- Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Clinical Trial Outcome Measures
Primary Measures
- The differences of tongue images between patients with malignant tumors and healthy people.
- Time Frame: 1 year
- Overall Survival (OS)
- Time Frame: 3 years
Secondary Measures
- Disease free survival(DFS)
- Time Frame: 1 year
Participating in This Clinical Trial
Inclusion Criteria
- 18≤age≤80 – Histologically or cytologically confirmed malignant tumor – No prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for malignant tumor – Subject volunteers to join the study, Signs informed consent, has good compliance and can cooperate with follow-up Exclusion Criteria:
- Two or more kinds of malignant tumors at the same time – Malignant tumor that has been treated by chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor therapy – Subjects who had other factors that might force them to terminate the research ahead of time, such as the development of other severe disease (including mental disease) that required combined treatment, seriously abnormal laboratory examination value, and family or social factors that might affect the subject safety or experimental data collection, as judged by the researchers
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Zhejiang Cancer Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Xiangdong Cheng, Professor; Chief physician – Zhejiang Cancer Hospital
- Overall Official(s)
- Xiangdong Cheng, MD, Principal Investigator, Zhejiang Cancer Hospital
- Overall Contact(s)
- Xiangdong Cheng, MD, 0086-571-88128041, Chengxd516@126.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.